|
EP3706772A1
|
|
Compositions and method for the treatment of x-linked centronuclear myopathy
|
|
EP3281957A1
|
|
Aza-capped cyclodextrins and process of preparing them
|
|
EP3273495A1
|
|
Device comprising nanowires
|
|
EP3257864A1
|
|
Metabolically stable spexin peptide analogs
|
|
EP3257863A1
|
|
Flourous metabolically stable peptide analogs
|
|
EP3244532A1
|
|
Magnetic operational amplifier
|
|
EP3289074A1
|
|
Clinical gene signature-based human cell culture model and uses thereof
|
|
EP3236547A1
|
|
Random lasing photo-curable composition for use as random lasing gain medium
|
|
EP3225590A1
|
|
Highly selective artificial neurotransmitter receptors
|
|
EP3225986A1
|
|
Process and apparatus for noninvasive estimation of time of death
|
|
EP3225257A1
|
|
Amphiphilic monomers based nanovectors and their use for sirna delivery
|
|
EP3171388A1
|
|
Time gated image intensifier tube
|
|
WO2016030623A1
|
|
Method for producing hydrogen by means of dark fermentation from biomass from the wine-producing industry, without using a microbial consortium
|
|
EP3108835A1
|
|
Injection device of bone cement for percutaneous vertebroplasty
|
|
EP3108833A1
|
|
Method for controlling the viscosity of orthopedic bone cement
|
|
WO2015189402A1
|
|
Disintegratable core/shell silica particles for encapsulating and releasing bioactive macromolecules
|
|
EP3085785A1
|
|
Dynamin 2 inhibitor for the treatment of duchenne's muscular dystrophy
|
|
EP3047905A1
|
|
Method for preparing highly nitrogen-doped mesoporous carbon composites
|
|
EP3055675A1
|
|
Device and method for time-resolved fluorescence measurement for the high-throughput screening of specimens
|
|
EP2995612A1
|
|
Novel non-natural amino acids, their process of preparation and uses thereof
|
